A Study of Buntanetap in Participants With PD
RecruitingNCT07284784Phase: PHASE2, PHASE3Started 2026-01-09
Summary
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll
Eligibility
Sex
ALL
Min Age
40 Years
Max Age
85 Years
Locations
University of Alabama at BirminghamBirmingham, Alabama, United States
Banner Sun Health Research Institute - Cleo Roberts Center fSun City, Arizona, United States
Parkinson's & Movement Disorder Institute (PMDI) - Orange CoFountain Valley, California, United States
Cenexel Rocky Mountain Clinical ResearchEnglewood, Colorado, United States
New England Institute for Clinical Research (Ki Health PartnStamford, Connecticut, United States
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT07284784